Streetbeat News

SPRC

SciSparc Ltd.

Industry

Biotechnology

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Open

0.23

Mkt cap

2.6M

Volume

430K

High

0.25

P/E Ratio

-0.02

52-wk high

14.22

Low

0.22

Div yield

N/A

52-wk low

0.21

SciSparc Ltd. (NASDAQ:SPRC) stock surged after announcing the launch of a clinical trial for a treatment combining CBD and the company's proprietary compound for autism symptoms. The trial will involve 60 participants aged 5-18. Additionally, SciSparc recently signed a letter of intent to merge with an Israeli vehicle importer. SPRC shares have seen heavy trading, with volumes far exceeding the 100-day average.

Portfolio Pulse from Erica Kollmann

November 24, 2023 | 4:19 pm

Shares of SciSparc Ltd. (SPRC) were halted due to a circuit breaker, which typically occurs when there is an unusual movement in the stock price, either up or down, triggering a temporary pause in trading to prevent excessive volatility.

Portfolio Pulse from Benzinga Newsdesk

November 24, 2023 | 3:18 pm

U.S. stock indices rose on Wednesday, with the Dow Jones up by 0.5%, NASDAQ by 0.46%, and S&P 500 by 0.41%. SciSparc Ltd surged 16.80% after announcing a non-binding letter of intent to merge with an Israeli vehicle importer. Deere & Company's stock fell 3.11% post Q4 FY23 results showing decreased net sales and revenue. Baidu Inc. climbed 5.91% due to positive Q3 financial results and analyst coverage. Marathon Digital Holdings rose 5.92% amid an uptrend in the crypto market. Tesla Inc. dropped 2.90% following legal concerns over its Autopilot system.

Portfolio Pulse from Benzinga Neuro

November 23, 2023 | 1:42 am

Urban Outfitters, Inc. (NASDAQ:URBN) shares dropped by approximately 10% despite reporting Q3 earnings of 88 cents per share, above the consensus estimate of 82 cents, and record sales of $1.28 billion, surpassing expectations of $1.26 billion. Other stocks experienced movements in Wednesday's mid-day session, with notable gainers including AgileThought, Inc. (AGIL), PaxMedica, Inc. (PXMD), and SciSparc Ltd. (SPRC), among others. Losers included Alterity Therapeutics Limited (ATHE), MIRA Pharmaceuticals, Inc. (MIRA), and Tharimmune, Inc. (THAR), with companies like Guess?, Inc. (GES), Nordstrom, Inc. (JWN), and Deere & Company (DE) also reporting declines after their financial results.

Portfolio Pulse from Lisa Levin

November 22, 2023 | 7:03 pm

Israel's cannabis industry is growing, with increased medical cannabis prescriptions post-Gaza war. ICD Pharma, Tikun Olam Cannbit (TKUNF), and Syqe Medical are key players, with Syqe set for a $650 million acquisition by Philip Morris. IM Cannabis Corp. (IMCC) was the first Israeli cannabis company on NASDAQ. Curaleaf Holdings (CURLF) and Aurora Cannabis (ACB) are North American companies involved in Israel's market. SciSparc Ltd. (SPRC) plans to merge with an unnamed vehicle importer, expecting the importer to hold 80% of the combined entity post-merger and financing round.

Portfolio Pulse from Jelena Martinovic

November 22, 2023 | 3:18 pm

U.S. stocks opened higher with the Dow Jones gaining 150 points. Communication services shares led the gains, while energy shares lagged. U.S. initial jobless claims fell sharply to 209,000, beating expectations. AgileThought, Inc. (AGIL), SciSparc Ltd. (SPRC), and Eiger BioPharmaceuticals, Inc. (EIGR) saw significant stock increases. Conversely, Nogin, Inc. (NOGN), Alterity Therapeutics Limited (ATHE), and Guess?, Inc. (GES) experienced notable declines. Oil prices dropped, and gold saw a slight increase.

Portfolio Pulse from Lisa Levin

November 22, 2023 | 2:43 pm

SciSparc (SPRC) shares surged 43% following the announcement of a non-binding letter of intent to merge with an Israeli vehicle importer. Guess? (GES) shares fell 15% after reporting disappointing Q3 results and lower Q4 EPS guidance. dLocal (DLO) shares dropped 18% due to poor Q3 results and reaffirmed FY23 revenue guidance that fell short of expectations.

Portfolio Pulse from ryanfaloona@benzinga.com

November 22, 2023 | 1:50 pm

SciSparc Ltd (NASDAQ:SPRC) stock rose after announcing a non-binding letter of intent to merge with an unnamed vehicle importer company in Israel. The merger will be a reverse triangular merger, and SciSparc plans to transfer its pharmaceutical technologies and product candidates to a new legal entity. The company highlighted that its revenues for the first half of 2023 exceeded $52 million. SciSparc's stock increased by 25.5% to $8.06 following the news.

Portfolio Pulse from Adam Eckert

November 22, 2023 | 1:43 pm

SciSparc's stock price has risen following the announcement of a non-binding letter of intent to merge with an Israeli vehicle importer. This strategic move could potentially expand SciSparc's market presence and diversify its operations.

Portfolio Pulse from Benzinga Newsdesk

November 22, 2023 | 1:42 pm

SciSparc, a clinical-stage pharmaceutical company, has signed a non-binding letter of intent to merge with an unnamed vehicle importer company in Israel. The merger aims to expand SciSparc's business operations. The impact on SciSparc's stock (SPRC) will depend on investor perception of the strategic fit and potential synergies between the pharmaceutical and vehicle import businesses.

Portfolio Pulse from Benzinga Newsdesk

November 22, 2023 | 12:43 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.